肺癌患者血小板中VEGF与TSP-1测定的临床应用价值

The Application Value of Platelet VEGF and TSP-1 Detections in the Lung Cancers

目的探讨血小板中血管内皮细胞生长因子(VEGF)与凝血酶敏感蛋白-1(TSP-1)测定在肺癌进展中的临床应用价值。方法采用酶联免疫吸附实验(ELISA)检测71例最终确诊为肺癌的患者及35例健康体检者的血小板与贫血小板血浆(PPP)中的VEGF与TSP-1水平。结果与正常对照组比较,肺癌未转移与转移患者血小板中VEGF水平及VEGF/TSP-1比值均明显升高(P<0.05);肺癌转移患者血小板中VEGF及VEGF/TSP-1比值高于肺癌未转移患者(P<0.05);肺癌未转移与转移患者血小板中TSP-1水平明显低于对照组(P<0.05);肺癌组与对照组所有个体的贫血小板血浆中的VEGF与TSP-1均低于检测下限而未能检出。结论肺癌患者血小板中VEGF与TSP-1平衡关系发生改变,并且血小板VEGF与VEGF/TSP-1水平有助于反映肺癌的转移情况。

Objective To investigate the clinical application of platelet vascular endothelial growth factor（VEGF）and TSP-1 determination in the progression of lung cancers. Methods The levels of VEGF and TSP-1 in platelets and platelet-poor plasma（PPP）in 71 patients with lung cancers and 35 healthy controls were determined by ELISA method. Results The levels of platelet VEGF and VEGF/TSP-1 in patients with unmetastatic lung cancers and metastatic lung cancers were significantly higher than those in healthy controls （P〈0.05）; the levels of platelet VEGF and VEGF/TSP-1 in patients with metastatic lung cancers were significantly higher than those in patients with unmetastatic lung cancers （P〈0.05）. Moreover,the levels of platelet TSP-1 in patients with unmetastatic lung cancers and metastatic lung cancers were remarkably lower than those in healthy controls （P〈0.05）. However,the PPP VEGF and TSP-1 in the patients and control group were undetactable （〈7.18 pg/ml）. Conclusions The balance between the levels of VEGF and TSP-1 is shifted in the peripheral blood of patients with lung cancers,and the levels of platelet VEGF and VEGF/TSP-1 will help to reflect the progression of lung cancers.